No profile photo available

TingTing Hong, MD, PhD

Languages spoken: Chinese, English

TingTing Hong, MD, PhD, is an Associate Professor of Pharmacology & Toxicology in the College of Pharmacy, University of Utah. Dr. Hong received her MD and clinical training from the Peking University, and her PhD in Pharmacology from the University of Michigan. After completing her postdoctoral training in the Cardiovascular Research Institute at the University of California San Francisco, Dr. Hong joined Cedars-Sinai Medical Center and University of California Los Angeles in 2013 as a faculty member before her recruitment to the University of Utah in 2020. Dr. Hong has a broad background in medicine, physiology, pharmacology, and cell biology with expertise in the field of cardiovascular research. The Hong Lab focuses on the basic cell biology of cardiomyocytes, with particular interest in the transverse tubule membrane microdomain organization and regulation in normal and diseased cardiac myocytes. Combining transgenic mouse models, biochemical assays with high-resolution imaging techniques, the Hong Lab explores novel mechanisms of dynamic microdomain regulation and remodeling during heart failure progression, aiming to develop new diagnostic and therapeutic tools for heart failure.

Education History

Diploma University of Michigan, Ann Arbor
 PHD
Diploma Peking University
 MS
Diploma Beijing Medical University
 MD

Selected Publications

Journal Article

  1. Hamouche R, Tatum SM, Dranow E, Maschek JA, Kyriakopoulos CP, Shankar TS, Visker JR, Ling J, Sideris K, Selzman CH, Kfoury AG, Stehlik J, Alharethi R, Fang JC, Hong T, Navankasattusas S, Rondina MT, Holland WL, Summers SA, Drakos SG, Tseliou E (2025). The Role of Sphingolipids in Myocardial Recovery Mediated by Mechanical Unloading and Circulatory Support. JACC Basic Transl Sci, 11(1), 101435.
  2. Khan MS, Smego D, Li J, Ishidoya Y, Offei E, Ruiz Castillo MS, Hirahara AM, Balmaceda P, Hunter J, Athavale A, Revelo MP, Palatinus JA, Selzman CH, Ranjan R, Hong T, Dosdall DJ, Shaw RM (2025). AAV9-cBIN1 gene therapy rescues chronic heart failure due to ischemic cardiomyopathy in a canine model. Commun Med (Lond), 5(1), 93.
  3. Baum R, Nguyen VD, Maalouf M, Shimura D, Waghalter M, Srapyan S, Jin Q, Kuzmanovich L, Gaffney AT, Bell BR, Xiao S, Palatinus JA, Klber AG, Grintsevich EE, Hong T, Shaw RM (2024). A truncated isoform of Connexin43 caps actin to organize forward delivery of full-length Connexin43. J Cell Biol, 224(3).
  4. Balmaceda P, Hitzeman TC, Shaw KE, Kolhepp LM, Killeen M, Fang JC, Butler J, Hernandez AF, Hong T, Shaw RM (2025). Design of the First in Human Gene Therapy Trial of TLT-101 for Chronic Heart Failure (FIGHT-HF). JACC Basic Transl Sci, 10(3), 276-278.
  5. Visker JR, Tseliou E, Kyriakopoulos CP, Hamouche R, Yin M, Ling J, Shankar TS, Kwan E, Cedeno-Rosaria L, Velasco-Silva JN, Sideris K, Kwak H, Hillas Y, Yannias E, Maneta E, Srinivasan H, Padilla L, Polishchuck G, Navankasattusas S, Tandar A, Ducker GS, Rutter J, Hong T, Shaw RM, Lui C, Welt FG, Drakos SG (2025). Peroxisome proliferator-activated receptor gamma ( PPARG )-mediated myocardial salvage in acute myocardial infarction managed with left ventricular unloading and coronary reperfusion. bioRxiv.
  6. Li J, Balmaceda P, Ha T, Visker JR, Maalouf N, Kwan E, Hoareau GL, Accad M, Ranjan R, Selzman CH, Drakos SG, Shaw RM, Hong T Corresponding author (2024). Cardiac bridging integrator 1 gene therapy rescues chronic non-ischemic heart failure in minipigs. NPJ Regen Med, 9(1), 36.
  7. Li J, Richmond B, Cluntun AA, Bia R, Walsh MA, Shaw K, Symons JD, Franklin S, Rutter J, Funai K, Shaw RM, Hong T Corresponding author (2023). Cardiac gene therapy treats diabetic cardiomyopathy and lowers blood glucose. JCI Insight, 8(18).
  8. Khan MS, Smego D, Ishidoya Y, Hirahara AM, Offei E, Ruiz Castillo MS, Gharbia O, Li H, Palatinus JA, Krueger L, Hong T, Hoareau GL, Ranjan R, Selzman CH, Shaw RM, Dosdall DJ (2023). A canine model of chronic ischemic heart failure. Am J Physiol Heart Circ Physiol, 324(6), H751-H761.
  9. Hogen T, Li J, Balmaceda P, Ha T, Brown GW, Shaw RM, Hong T Corresponding author (2023). Echocardiography Recording in Awake Miniature Pigs. J Vis Exp, (195).
  10. Palatinus JA, Valdez S, Taylor L, Whisenant C, Selzman CH, Drakos SG, Ranjan R, Hong T, Saffitz JE, Shaw RM (2023). GJA1-20k Rescues Cx43 Localization and Arrhythmias in Arrhythmogenic Cardiomyopathy. Circ Res, 132(6), 744-746.
  11. Pacheco C, Wei J, Shufelt C, C Hitzeman T, Cook-Wiens G, Pepine CJ, Handberg E, Anderson RD, Petersen J, Hong T, M Shaw R, Bairey Merz CN (2021). Association of coronary microvascular dysfunction and cardiac bridge integrator 1, a cardiomyocyte dysfunction biomarker. Clin Cardiol, 44(11), 1586-1593.
  12. Shimura D, Nuebel E, Baum R, Valdez SE, Xiao S, Warren JS, Palatinus JA, Hong T, Rutter J, Shaw RM (2021). Protective mitochondrial fission induced by stress-responsive protein GJA1-20k. Elife, 10.
  13. Xiao S, Shimura D, Baum R, Hernandez DM, Agvanian S, Nagaoka Y, Katsumata M, Lampe PD, Kleber AG, Hong T, Shaw RM (2020). Auxiliary trafficking subunit GJA1-20k protects connexin-43 from degradation and limits ventricular arrhythmias. J Clin Invest, 130(9), 4858-4870.
  14. Li J, Agvanian S, Zhou K, Shaw RM, Hong T Corresponding author (2020). Exogenous Cardiac Bridging Integrator 1 Benefits Mouse Hearts With Pre-existing Pressure Overload-Induced Heart Failure. Front Physiol, 11, 708.
  15. Hitzeman TC, Xie Y, Zadikany RH, Nikolova AP, Baum R, Caldaruse AM, Agvanian S, Melmed GY, McGovern DPB, Geft DR, Chang DH, Moriguchi JD, Hage A, Azarbal B, Czer LS, Kittleson MM, Patel JK, Wu AHB, Kobashigawa JA, Hamilton M, Hong T, Shaw RM Corresponding author (2020). cBIN1 Score (CS) Identifies Ambulatory HFrEF Patients and Predicts Cardiovascular Events. Front Physiol, 11, 503.
  16. Liu Y, Zhou K, Li J, Agvanian S, Caldaruse AM, Shaw S, Hitzeman TC, Shaw RM, Hong T Corresponding author (2020). In Mice Subjected to Chronic Stress, Exogenous cBIN1 Preserves Calcium-Handling Machinery and Cardiac Function. JACC Basic Transl Sci, 5(6), 561-578.
  17. Epifantseva I, Xiao S, Baum RE, Klber AG, Hong T, Shaw RM (2020). An Alternatively Translated Connexin 43 Isoform, GJA1-11k, Localizes to the Nucleus and Can Inhibit Cell Cycle Progression. Biomolecules, 10(3).
  18. Cadar AG, Feaster TK, Bersell KR, Wang L, Hong T, Balsamo JA, Zhang Z, Chun YW, Nam YJ, Gotthardt M, Knollmann BC, Roden DM, Lim CC, Hong CC (2019). Real-time visualization of titin dynamics reveals extensive reversible photobleaching in human induced pluripotent stem cell-derived cardiomyocytes. Am J Physiol Cell Physiol, 318(1), C163-C173.
  19. Nikolova AP, Hitzeman TC, Baum R, Caldaruse AM, Agvanian S, Xie Y, Geft DR, Chang DH, Moriguchi JD, Hage A, Azarbal B, Czer LS, Kittleson MM, Patel JK, Wu AHB, Kobashigawa JA, Hamilton M, Hong T, Shaw RM Corresponding author (2018). Association of a Novel Diagnostic Biomarker, the Plasma Cardiac Bridging Integrator 1 Score, With Heart Failure With Preserved Ejection Fraction and Cardiovascular Hospitalization. JAMA Cardiol, 3(12), 1206-1210.
  20. Basheer WA, Fu Y, Shimura D, Xiao S, Agvanian S, Hernandez DM, Hitzeman TC, Hong T, Shaw RM (2018). Stress response protein GJA1-20k promotes mitochondrial biogenesis, metabolic quiescence, and cardioprotection against ischemia/reperfusion injury. JCI Insight, 3(20).
  21. Fu Y, Zhang SS, Xiao S, Basheer WA, Baum R, Epifantseva I, Hong T, Shaw RM (2017). Cx43 Isoform GJA1-20k Promotes Microtubule Dependent Mitochondrial Transport. Front Physiol, 8, 905.
  22. Basheer WA, Xiao S, Epifantseva I, Fu Y, Kleber AG, Hong T, Shaw RM (2017). GJA1-20k Arranges Actin to Guide Cx43 Delivery to Cardiac Intercalated Discs. Circ Res, 121(9), 1069-1080.
  23. Xu B, Fu Y, Liu Y, Agvanian S, Wirka RC, Baum R, Zhou K, Shaw RM, Hong T Corresponding author (2017). The ESCRT-III pathway facilitates cardiomyocyte release of cBIN1-containing microparticles. PLoS Biol, 15(8), e2002354.
  24. Fu Y, Shaw SA, Naami R, Vuong CL, Basheer WA, Guo X, Hong T Corresponding author (2016). Isoproterenol Promotes Rapid Ryanodine Receptor Movement to Bridging Integrator 1 (BIN1)-Organized Dyads. Circulation, 133(4), 388-97.
  25. Smyth JW, Zhang SS, Sanchez JM, Lamouille S, Vogan JM, Hesketh GG, Hong T, Tomaselli GF, Shaw RM (2014). A 14-3-3 mode-1 binding motif initiates gap junction internalization during acute cardiac ischemia. Traffic, 15(6), 684-99.
  26. Hong T, Yang H, Zhang SS, Cho HC, Kalashnikova M, Sun B, Zhang H, Bhargava A, Grabe M, Olgin J, Gorelik J, Marbn E, Jan LY, Shaw RM (2014). Cardiac BIN1 folds T-tubule membrane, controlling ion flux and limiting arrhythmia. Nat Med, 20(6), 624-32.
  27. Gao D, Zhang L, Dhillon R, Hong TT, Shaw RM, Zhu J (2013). Dynasore protects mitochondria and improves cardiac lusitropy in Langendorff perfused mouse heart. PLoS One, 8(4), e60967.
  28. Hong TT, Cogswell R, James CA, Kang G, Pullinger CR, Malloy MJ, Kane JP, Wojciak J, Calkins H, Scheinman MM, Tseng ZH, Ganz P, De Marco T, Judge DP, Shaw RM (2012). Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm, 9(6), 961-7.
  29. Hong TT, Smyth JW, Chu KY, Vogan JM, Fong TS, Jensen BC, Fang K, Halushka MK, Russell SD, Colecraft H, Hoopes CW, Ocorr K, Chi NC, Shaw RM (2011). BIN1 is reduced and Cav1.2 trafficking is impaired in human failing cardiomyocytes. Heart Rhythm, 9(5), 812-20.
  30. Smyth JW, Vogan JM, Buch PJ, Zhang SS, Fong TS, Hong TT, Shaw RM (2012). Actin cytoskeleton rest stops regulate anterograde traffic of connexin 43 vesicles to the plasma membrane. Circ Res, 110(7), 978-89.
  31. Chen S, Law CS, Grigsby CL, Olsen K, Hong TT, Zhang Y, Yeghiazarians Y, Gardner DG (2011). Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation, 124(17), 1838-47.
  32. Hong TT, Smyth JW, Gao D, Chu KY, Vogan JM, Fong TS, Jensen BC, Colecraft HM, Shaw RM (2010). BIN1 localizes the L-type calcium channel to cardiac T-tubules. PLoS Biol, 8(2), e1000312.
  33. Smyth JW, Hong TT, Gao D, Vogan JM, Jensen BC, Fong TS, Simpson PC, Stainier DY, Chi NC, Shaw RM (2009). Limited forward trafficking of connexin 43 reduces cell-cell coupling in stressed human and mouse myocardium. J Clin Invest, 120(1), 266-79.
  34. Ieda M, Tsuchihashi T, Ivey KN, Ross RS, Hong TT, Shaw RM, Srivastava D (2008). Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev Cell, 16(2), 233-44.
  35. Hong TT, Huang J, Barrett TD, Lucchesi BR (2007). Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis. Am J Physiol Heart Circ Physiol, 294(1), H145-55.
  36. Hong TT, Huang J, Driscoll E, Lucchesi BR (2006). Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis. J Cardiovasc Pharmacol, 48(5), 239-48.
  37. Hong TT, Huang J, Lucchesi BR (2005). Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. alfimeprase. Am J Physiol Heart Circ Physiol, 290(3), H959-67.
  38. Hong TT, Van Gorp CL, Cardin AD, Lucchesi BR (2004). Intimatan (dermatan 4,6-O-disulfate) prevents rethrombosis after successful thrombolysis in the canine model of deep vessel wall injury. Thromb Res, 117(3), 333-42.
  39. Hong TT, Huang J, Driscoll E, Lucchesi BR (2005). The antithrombotic effect of melagatran in combination with clopidogrel and/or aspirin (carotid artery primary thrombosis study). J Cardiovasc Pharmacol, 46(4), 526-33.
  40. Hong TT, White AJ, Lucchesi BR (2004). Dermatan disulfate (Intimatan) prevents complement-mediated myocardial injury in the human-plasma-perfused rabbit heart. Int Immunopharmacol, 5(2), 381-91.
  41. Hong TT, Driscoll EM, White AJ, Sherigill A, Giboulot TA, Lucchesi BR (2003). Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator. J Pharmacol Exp Ther, 306(2), 616-23.
  42. Hennan JK, Willens DE, Driscoll EM Jr, Hong TT, Giboulot T, Lucchesi BR (2003). Prevention of carotid artery thrombosis after oral administration of the glycoprotein IIb/IIIa antagonist CRL42796. J Cardiovasc Pharmacol, 42(1), 71-7.
  43. Hennan JK, Hong TT, Willens DE, Driscoll EM, Giboulot TA, Lucchesi BR (2002). Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796. Br J Pharmacol, 136(6), 927-37.
  44. Hennan JK, Hong TT, Shergill AK, Driscoll EM, Cardin AD, Lucchesi BR (2002). Intimatan prevents arterial and venous thrombosis in a canine model of deep vessel wall injury. J Pharmacol Exp Ther, 301(3), 1151-6.
  45. Sun N, Hong T, Zhang R, Yang X (2000). The effects of verapamil SR and bisoprolol on reducing the sympathetic nervous system's activity. Hypertens Res, 23(5), 537-40.

Review

  1. Li J, Richmond B, Hong T Corresponding author (2021). Cardiac T-Tubule cBIN1-Microdomain, a Diagnostic Marker and Therapeutic Target of Heart Failure. [Review]. Int J Mol Sci, 22(5).

Editorial

  1. Hong T, Shaw RM Corresponding author (2018). Editorial commentary: Extracellular vesicles in cardiovascular diagnosis and therapy. Trends Cardiovasc Med, 29(6), 324-325.
  2. Zadikany RH, Hong T, Shaw RM (2019). Heart failure: distinguishing failing myocardium from volume overload. Biomark Med, 13(9), 697-700.
  3. Fu Y, Xiao S, Hong T, Shaw RM (2015). Cytoskeleton regulation of ion channels. Circulation, 131(8), 689-91.

Letter

  1. Nikolova AP, Hong T, Shaw RM (2019). Letter by Nikolova et al Regarding Article, "Heart Failure With Preserved Ejection Fraction in Perspective". [Letter to the editor]. Circ Res, 125(4), e24-e25.